Core Insights - Amwell granted RSUs covering 76,198 shares of its Class A common stock to two new employees as an inducement for their employment [1][2] - The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over three years [1] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and offers integrated solutions for millions of patients, demonstrating scalability and dependable outcomes [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Financial Performance - Heartflow's shares experienced a significant surge of 66% [1] - The AI software platform focusing on heart disease secured $317 million through its IPO [1] Market Dynamics - Heartflow, an AI software platform specializing in heart disease, went public [1]

Core Insights - Health Catalyst reported revenue of $80.72 million for the quarter ended June 2025, reflecting a 6.4% increase year-over-year, and an EPS of $0.04, down from $0.12 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $80.53 million by 0.24%, while the EPS surpassed the consensus estimate of $0.03 by 33.33% [1] Revenue Breakdown - Professional services revenue was $27.85 million, slightly below the average estimate of $27.86 million, representing a year-over-year decline of 1.5% [4] - Technology revenue reached $52.88 million, exceeding the estimated $52.67 million, and showing an 11% increase compared to the previous year [4] Profitability Metrics - Adjusted Gross Profit for Professional Services was reported at $5.11 million, surpassing the average estimate of $4.09 million [4] - Adjusted Gross Profit for Technology was $34.85 million, slightly below the average estimate of $35.35 million [4] Stock Performance - Over the past month, Health Catalyst shares have returned -5.2%, contrasting with a +1.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Financial Data and Key Metrics Changes - The company reported Q2 2025 revenue of $80.7 million, representing a 6% year-over-year increase and exceeding guidance [31] - Adjusted EBITDA for Q2 2025 was $9.3 million, the highest in the company's history, and also above guidance [34] - The company revised its full-year 2025 revenue guidance to $310 million due to significant impacts from Medicaid and research funding cuts [6][7] - Adjusted gross margin for Q2 2025 was 50%, a decrease of approximately 30 basis points year-over-year [32] Business Line Data and Key Metrics Changes - Technology segment revenue for Q2 2025 was $52.9 million, reflecting an 11% year-over-year growth driven by recurring revenue from new and acquired clients [32] - Professional services revenue for Q2 2025 was $27.8 million, a 1% decline compared to Q2 2024 [32] - Adjusted technology gross margin was 66%, down approximately 140 basis points year-over-year, while adjusted professional services gross margin was 18%, down approximately 190 basis points year-over-year [32][34] Market Data and Key Metrics Changes - The company anticipates that the impacts of Medicaid and research funding cuts will be a headwind not only in 2025 but likely over the next few years [13] - The company has seen delays in signing new platform client contracts due to macroeconomic uncertainty and funding cuts [9][12] Company Strategy and Development Direction - The company is focused on improving profitability and has removed its previously shared 2028 revenue target of $500 million, emphasizing near-term profitability improvements [14] - The strategic focus is on expanding applications revenue, which has been growing at over 20% year-over-year, and leveraging the Ignite platform for cross-selling opportunities [16][17] - The company plans to complete the migration of platform clients to Ignite by mid-2026, which is expected to alleviate some revenue headwinds [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy despite current macroeconomic challenges, including inflation and funding cuts [6][14] - The company expects to maintain adjusted EBITDA guidance of $41 million for 2025, despite the revenue reduction [21] - Management acknowledged the need for clients to adjust to new funding realities, which may take time [52] Other Important Information - The company announced a restructuring plan that will impact approximately 9% of its workforce, aimed at improving profitability by over $40 million annually [20] - A new director, Justin Spencer, will join the board effective September 1, bringing relevant experience from the healthcare technology sector [29] - The CEO announced plans to retire effective June 30, 2026, after 15 years in the role [30] Q&A Session Summary Question: How is the Life Science business performing and what level of investment is needed for growth? - Management noted delays in late-stage opportunities in the CareVive business due to research funding cuts but remains confident in the differentiated offering [41][42] Question: Can you explain the market reaction to the recent Medicaid cuts? - Management highlighted a conservative approach among not-for-profit clients, which has led to delays in project initiation as they adjust to funding cuts [50][51] Question: What is the expected EBITDA for 2026? - Management indicated a run rate of approximately $60 million of adjusted EBITDA going into 2026, with potential for additional operating leverage [52][54] Question: What is the contribution of app layer client wins versus external client wins for new platform clients? - Approximately two-thirds of new platform clients have come from existing clients, reflecting strong cross-sell momentum [58][59] Question: How should investors think about growth rates for 2026 and beyond? - Management suggested that growth may be in the low single digits for 2026 due to ongoing macro headwinds, but expects a return to growth as the Ignite migration is completed [66][71]

Core Insights - Doximity is enhancing its capabilities in artificial intelligence by acquiring Pathway Medical for $63 million, aiming to improve its platform for healthcare professionals [1][4] - Pathway Medical has developed an AI-powered clinical reference tool that provides answers to medical questions based on a large structured dataset, which Doximity intends to integrate into its services [2][3] - The acquisition is expected to allow Doximity's platform to serve as a resource for doctors seeking clinical answers, expanding its functionality beyond networking and administrative tasks [3][4] Financial Details - The acquisition deal closed in late July, involving a cash payment of $26 million and potential additional equity grants of up to $37 million [4] Integration and Development - Doximity is actively integrating Pathway's technology, with testing of a combined product already underway involving thousands of doctors [4]

Hackers have stolen login credentials from thousands of people working with the UK’s National Health Service, putting the organization at risk of further cyberattacks, researchers say https://t.co/KmriZpmEfV ...

Key Takeaways The U.S. market slid slightly yesterday as investors weighed fresh earnings reports, economic data and tariff news. President Trump will be announcing new tariffs on semiconductor and pharmaceutical imports soon, adding to existing trade tensions. In this uncertain environment—marked by geopolitical risks and policy shifts —value investing stands out as a smart strategy. Value investing means buying stocks that are priced below what they are really worth. It works on the idea that markets ofte ...

American Well (AMWL) Q2 2025 Earnings Call August 05, 2025 05:00 PM ET Speaker0Good day, and thank you for standing by. Welcome to the AmWell Second Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded.I would now like to hand the conference over to your speaker today, Sue Dooley, Head of Investor Relations. Please go ...

Financial Results Announcement - Medtronic plc will report its financial results for the first quarter of fiscal year 2026 on August 19, 2025, following the end of the quarter on July 25, 2025 [1] - The company plans to announce results for the subsequent quarters on November 18, 2025, February 17, 2026, and May 20, 2026 [1] Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [2] - The company's mission is to alleviate pain, restore health, and extend life, addressing 70 health conditions through various technologies including cardiac devices, surgical robotics, and patient monitoring systems [2] - Medtronic aims to deliver innovative technologies that transform lives, impacting two people every second [2]

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/ve8zytc3/. A webcast repla ...